Copan, putting Covid-19 challenges behind and setting up for the post-pandemic scenario
PR88941
BRESCIA, Italy, April 10, 2021 /PRNewswire=KYODO JBN/ --
With an email to the main distributors, Copan group's CEO describes how the
ramp-up of Covid-19-related products has been concluded, and how the company is
now reorganizing to face post-pandemic challenges.
Photo - https://mma.prnewswire.com/media/1484617/Produzione_UTM_Copan_3.jpg
Logo - https://mma.prnewswire.com/media/1484615/CopanHD_Logo.jpg
Last Tuesday, Copan partners received an email signed by Copan's CEO Stefania
Triva herself. Certainly, it was not the first email they received from the
leader in preanalytics last year. Still, this time the communication tried to
put a full stop to pandemic-related struggles, informing about the
accomplishment of 2020 common goals and reorganizing the company and its
network for the years to come.
"We worked non-stop to expand our production," said Stefania Triva, describing
the global actions taken by the company and already explained in a video [
https://youtu.be/Riakz1O742k ] published in January. "Thanks to these efforts,
I am very proud to announce that the goal of reaching one billion of each
flocked and classic swabs produced per year has now been accomplished.
Likewise, the target of half a billion of transport media manufactured per year
is going to be reached soon." As written in the email, this represents a
pivotal role for Copan, as there's now the chance to restore product lines that
were on standby to prioritize Covid-19 related products.
Anyway, other challenges are just around the corner, as Covid-19 has been the
access point to preanalytics for new players worldwide. While the competition
in the field increased dramatically, "Preanalytics and sample quality
importance became public knowledge," she continues. The value of screening and
prevention programs has been permanently recognized, and a maintained demand
for biological collection and transport products for the following years is
foreseeable. "We believed and invested in preanalytics way earlier than
everybody else; behind our quality products, there are 40 years of expertise,
investments, scientific reliability, and a solid network of healthcare
professionals and partners to collaborate with," states Copan's CEO. This
approach has been adopted even during last year, with the release of innovative
products as UniVerse(TM), the automation that helped healthcare professionals
in processing Covid-19 samples.
Concluding, Stefania Triva is confident for the future of Copan: "We'll be able
to pick up where we left off, driving preanalytics development to cope with the
challenges of the years ahead."
Surely, across the horizon new challenges appeared, and we shall see what Copan
has in store for the future. Contact us for more details.
About Copan
Copan is dedicated to developing high-quality sample collection products for
infectious diseases, human genomics, environmental and forensic applications,
along with automated workflow solutions.
Our ideas drove 40 years of progress in the field of preanalytics, resulting in
the development of meaningful products tailored to fit any need. Among them,
our patented FLOQSwabs(R) reinvented sample collection and transport, while the
WASPLab(R) automation ecosystem revolutionized laboratory workflow.
Today, Copan is still eager to continue this innovation, providing quality
products, customized services, and prime solutions to improve patients' health.
SOURCE Copan Italia SpA
CONTACT: Marco Barbariga, +39 3351336617, Marco.barbariga@copangroup.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。